Merck invests €50m at Italian plant in Bari

To meet growing demand for biopharmaceuticals

German giant Merck plans to invest €50m at its Italian production site in Bari, Italy to meet rising demand for biopharmaceuticals.

The new facility in Bari is to be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials and ampoules.

Within Merck Serono’s global biotech production network, the Bari site is part of fill & finish operations alongside the facilities in Darmstadt, Germany and Aubonne, Switzerland. According to Merck, the drugs produced within this global network are seeing long-term growing demand, especially for medicines used to treat infertility.

'This is part of our growth plans for Merck and for the Merck Serono division in particular here in Bari, where we have excellent conditions thanks to highly skilled employees and a very good infrastructure,' said Karl-Ludwig Kley, Chairman of the Executive Board of Merck.

'Patients will also benefit from this investment as we secure the supply of drugs that improve the quality of life of people around the globe.'

Biotech products account for more than 50% of the sales of its Merck Serono division.